BioXcel Therapeutics Stock Price, News & Analysis (NASDAQ:BTAI)

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last twelve months. There are currently 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BTAI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BTAI, but not buy additional shares or sell existing shares.
View BTAI analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 12 month price targets for BioXcel Therapeutics' stock. Their BTAI share price targets range from $11.00 to $40.00. On average, they expect the company's stock price to reach $23.88 in the next year. This suggests a possible upside of 543.5% from the stock's current price.
View analysts price targets for BTAI or view top-rated stocks among Wall Street analysts.

BioXcel Therapeutics' stock was trading at $21.48 at the beginning of 2023. Since then, BTAI stock has decreased by 82.7% and is now trading at $3.71.
View the best growth stocks for 2023 here.

BioXcel Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 5,080,000 shares, a decrease of 12.6% from the October 31st total of 5,810,000 shares. Based on an average daily volume of 3,130,000 shares, the short-interest ratio is currently 1.6 days. Approximately 25.1% of the shares of the company are short sold.
View BioXcel Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our BTAI earnings forecast.

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) posted its earnings results on Monday, August, 14th. The company reported ($1.83) EPS for the quarter, missing analysts' consensus estimates of ($1.72) by $0.11. The company earned $0.46 million during the quarter, compared to analysts' expectations of $0.42 million. BioXcel Therapeutics had a negative trailing twelve-month return on equity of 890.63% and a negative net margin of 17,037.44%. The firm's revenue for the quarter was up 45600.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.35) earnings per share.

iShares Neuroscience and Healthcare ETF holds 2,477 shares of BTAI stock, representing 0.39% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).

(BTAI) raised $60 million in an IPO on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

BioXcel Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (9.23%), Ameriprise Financial Inc. (2.28%), Northern Trust Corp (0.77%), Adage Capital Partners GP L.L.C. (0.68%), Charles Schwab Investment Management Inc. (0.47%) and Bank of New York Mellon Corp (0.44%). Insiders that own company stock include Bioxcel Llc, Frank Yocca, Javier Rodriguez, Krishnan Nandabalan, Richard I Steinhart, Vimal Mehta and Vincent O'neill.
View institutional ownership trends.

Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.